Laprophan Group announced it completed the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specializing in specialty medicines, dossier development, complex formulations, and value-added pharmaceutical solutions. The financial terms of the transaction were not disclosed.
Rivopharm generates annual revenue of approximately $100 million and operates its own industrial manufacturing site. The acquisition marks Laprophan’s first acquisition in Europe and represents a major milestone in the company’s international expansion strategy.
The transaction was completed through Europhan, Laprophan’s Luxembourg-based European platform. Laprophan said the deal strengthens its European footprint and supports its ambition to build a differentiated international pharmaceutical platform spanning Europe, Africa, the Middle East, and selected global markets.
Laprophan already has an international presence through offices in India, the United Arab Emirates, and Côte d’Ivoire. With Rivopharm, the company adds a Swiss industrial and development base, along with European subsidiaries including Rivopharm UK in the United Kingdom, Holsten Pharma in Germany, and Sanoswiss in Lithuania.
Rivopharm manages a proprietary portfolio of approximately 125 molecules and nearly 1,500 SKUs distributed across more than 30 countries. The company operates an FDA-, TGA-, Swissmedic-, and EU-approved manufacturing facility in Lugano, Switzerland.
Laprophan said the combination brings together two complementary businesses with differentiated geographic footprints, industrial capabilities, and commercial, regulatory, and operational synergies. The transaction also strengthens Laprophan’s capabilities across pharmaceutical development, manufacturing, commercialization, and out-licensing partnerships.
Integration efforts are already underway, with both companies working together to support a smooth transition and advance joint strategic priorities. Laprophan said the acquisition also diversifies its business model and expands its presence in the B2B pharmaceutical segment.
BNP Paribas acted as exclusive financial advisor to Laprophan, with A&O Shearman serving as legal counsel. Pharmacloud, together with Jenson and Orbsen, provided commercial, regulatory, and operational due diligence services, while PwC provided financial, tax, HR, and pensions due diligence services.
Rothschild & Co acted as exclusive financial advisor to Rivopharm, with White & Case serving as legal counsel. PwC provided financial due diligence services.
KEY QUOTES:
“This acquisition is a defining moment in Laprophan’s history. It marks a new stage in our ambition to build an international pharmaceutical group rooted in Morocco, with strong industrial capabilities, scientific expertise and a long-term commitment to improving access to high-quality medicines. For more than 75 years, Laprophan has grown on solid foundations: industrial excellence, trusted relationships with healthcare professionals and a continuous commitment to innovation. With Rivopharm, we are taking a strategic step forward by integrating a recognized European platform with complementary industrial, technical and regulatory capabilities. This combination strengthens our international presence, diversifies our business model and accelerates our development in the B2B pharmaceutical segment. Together, Laprophan and Rivopharm are well positioned to build a stronger, more competitive and more diversified pharmaceutical group, able to serve partners and patients across multiple markets.”
Dr. Farid Bennis, Chairman of Laprophan Group
“Rivopharm was built with a clear ambition: to create an independent European pharmaceutical platform combining innovation, development expertise, manufacturing excellence and international partnerships. Today, by joining forces with Laprophan, we are taking that vision to the next level. Together, we bring highly complementary capabilities, strong entrepreneurial cultures and a shared commitment to long-term value creation. This partnership will enable us to accelerate our international expansion, unlock new opportunities for our products and partners, and build a diversified pharmaceutical group with a truly global reach. I am particularly proud that Rivopharm’s people, capabilities and European footprint will play a central role in shaping this exciting new chapter.”
Piero Poli, CEO of Rivopharm
